Journal article

Human IFN-gamma immunity to mycobacteria is governed by both IL-12 and IL-23

Ruben Martinez-Barricarte, Janet G Markle, Cindy S Ma, Elissa K Deenick, Noe Ramirez-Alejo, Federico Mele, Daniela Latorre, Seyed Alireza Mandaviani, Caner Aytekin, Davood Mansouri, Vanessa L Bryant, Fabienne Jabot-Hanin, Caroline Deswarte, Alejandro Nieto-Patlan, Laura Surace, Gaspard Kerner, Yuval Itan, Sandra Jovic, Danielle T Avery, Natalie Wong Show all

Science Immunology | AMER ASSOC ADVANCEMENT SCIENCE | Published : 2018

University of Melbourne Researchers

Grants

Awarded by National Institute of Allergy and Infectious Diseases (NIAID)


Awarded by National Center for Advancing Sciences (NCATS) of the NIH


Awarded by European Research Council


Awarded by Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence


Awarded by French National Research Agency (ANR)


Awarded by ANR-TBPATHGEN


Awarded by ANR-IFNPHOX


Awarded by ANR-GENMSMD


Awarded by NIAID


Awarded by NIH Translational Science Award (CTSA) program


Awarded by Swiss National Science Foundation


Awarded by National Council of Science and Technology of Mexico (CONACYT)


Awarded by NIH


Awarded by Japanese Society for the Promotion of Science


Funding Acknowledgements

The Laboratory of Human Genetics of Infectious Diseases was supported by grants from the National Institute of Allergy and Infectious Diseases (NIAID) grant numbers 5R37AI095983, R01AI089970, and K99AI127932; the National Center for Research Resources and the National Center for Advancing Sciences (NCATS) of the NIH grant number UL1TR001866; the Rockefeller University; the St. Giles Foundation; the European Research Council (ERC-2010-AdG-268777 and grant no. 323183); Institut National de la Sante et de la Recherche Medicale (INSERM), Paris Descartes University; the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID); and the French National Research Agency (ANR) under the "Investissement d'avenir" program (grant ANR-10-IAHU-01), ANR-TBPATHGEN (grant ANR-14-CE14-0007-01), ANR-IFNPHOX (grant ANR13-ISV3-0001-01), and ANR-GENMSMD (grant ANR16-CE17-0005-01). This work was supported by NIAID award no. U19AI118626 (to A.S. and F.S.). J.G.M. was funded by the Canadian Institutes of Health Research, the NIH Translational Science Award (CTSA) program (no. UL1 TR000043), the Swiss National Science Foundation (grant no. IZKOZ3_173586), the Charles H. Revson Foundation, and the NIAID (1K99AI127932-01A1). R.M.-B. was supported by the European Molecular Biology Organization (EMBO). N.R.-A. was supported by the National Council of Science and Technology of Mexico (CONACYT, 264011) and the Stony Wold-Herbert Fund Fellowship Grant. Y.I. was supported by the AXA Research Fund. S.G.T., E.K.D., and C.S.M. are supported by research grants and fellowships from the National Health and Medical Research Council of Australia (S.G.T., C.S.M., and E.K.D.) and the Office for Health and Medical Research of the State Government of NSW Australia (C.S.M.). A.S. is supported by NIH research grant HHSN272200900044C. J.B. is supported by SRC2017. The Institute for Research in Biomedicine and F.S. are supported by the Helmut Horten Foundation. S.O. was supported by the Aid for Scientific Research Grant from the Japanese Society for the Promotion of Science (16H05355) and the Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development.